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The type 2 cannabinoid receptor (CB2) is a member of the endocannabinoid system
and is known for its important role in (neuro)inflammation. A PET-imaging agent
that allows in vivo visualization of CB2 expression may thus allow quantification of
neuroinflammation. In this paper, we report the synthesis, radiosynthesis, biodistribution
and in vitro evaluation of a carbon-11 ([11C]MA2) and a fluorine-18 ([18F]MA3) labeled
analog of a highly potent N-arylamide oxadiazole CB2 agonist (EC50 = 0.015 nM). MA2
and MA3 behaved as potent CB2 agonist (EC50: 3 nM and 0.1 nM, respectively) and
their in vitro binding affinity for hCB2 was found to be 87 nM and 0.8 nM, respectively.
Also MA3 (substituted with a fluoro ethyl group) was found to have higher binding affinity
and EC50 values when compared to the originally reported trifluoromethyl analog 12.
[11C]MA2 and [18F]MA3 were successfully synthesized with good radiochemical yield,
high radiochemical purity and high specific activity. In mice, both tracers were efficiently
cleared from blood and all major organs by the hepatobiliary pathway and importantly
these compounds showed high brain uptake. In conclusion, [11C]MA2 and [18F]MA3
are shown to be high potent CB2 agonists with good brain uptake, these favorable
characteristics makes them potential PET probes for in vivo imaging of brain CB2
receptors. However, in view of its higher affinity and selectivity, further detailed evaluation
of MA3 as a PET tracer for CB2 is warranted.
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INTRODUCTION
The two types of cannabinoid receptors, CB1 and CB2, together with their endogenous lipid ligands
(endocannabinoids) and all proteins responsible for synthesis, transport and degradation of these
endocannabinoids represent the endocannabinoid system (ECS) (Rodríguez de Fonseca et al., 2005;
Mackie, 2008). CB1 and CB2 are both G-protein coupled receptors, but exhibit different expression
patterns and signaling profiles. CB1 receptors aremainly located in brain and are responsible for the
psychoactive effects of cannabinoids (Piomelli, 2003), whereas cannabinoid’s immunomodulatory
activity is assigned to CB2 receptors, which are predominantly expressed on β-lymphocytes and
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organs and tissues related to the immune system such as the
spleen and lymph nodes (Lynn and Herkenham, 1994; Galiegue
et al., 1995).
In addition, low levels of CB2 mRNA and protein have
been detected in healthy brain in Purkinje cells of the
cerebellum, hippocampal neurons, and various nuclei of the
brain stem (Atwood and Mackie, 2010). This may indicate
that the physiological role of CB2 in the central nervous
system (CNS) has been underestimated and that both CB1
and CB2 may control central functions. CB2 is, however, up-
regulated in the CNS under neuroinflammation. This CB2
overexpression has been predominantly assigned to microglia,
the resident immune cells of the brain, and alters depending
on their activation state(Cabral and Griffin-Thomas, 2009;
Atwood and Mackie, 2010). CB2-positive microglia have been
detected in β-amyloid plaques of Alzheimer’s disease patients
(Ramirez et al., 2005), in spinal cords of an amyotrophic
lateral sclerosis (ALS) mouse model (Shoemaker et al., 2006),
in active plaques of patients with multiple sclerosis (MS)
(Benito et al., 2007) and in striatal lesions of Huntington’s
disease (HD) transgenic mouse models and patients (Palazuelos
et al., 2009). Moreover, selective CB2 activation results in a
decrease of microglial activation in HD and ALS transgenic
mouse models and appears to be effective in reducing
neurodegeneration (Shoemaker et al., 2006; Palazuelos et al.,
2009; Sagredo et al., 2009). These observations suggest that
therapeutic modulation of CB2 may be a new promising
treatment for neuropathogenic disorders characterized by a
neuroinflammatory component.
Various CB2-selective drugs and companion PET-imaging
agents have been developed over the past years (Evens et al.,
2008, 2009, 2011; Horti et al., 2010; Turkman et al., 2012;
Slavik et al., 2015, 2016; Moldovan et al., 2016). Horti and
co-workers demonstrated binding of [11C]A-836339 to CB2 in
lipopolysaccharide (LPS)-induced neuroinflammation and AD
mouse models (Horti et al., 2010). Our group previously showed
[11C]NE40 had CB2-specific retention in the spleen of mice
(Evens et al., 2009) and in a rat model with local overexpression
of a human inactive CB2 variant (Evens et al., 2012). Rühl
et al. reported the synthesis of a 18F-labeled N-aryl-oxadiazolyl-
propionamide derivative with low nanomolar binding affinity for
hCB2 (Rühl et al., 2012). The non-radioactive compound was
shown to bind CB2 in mouse spleen in an autoradiographic study
using [3H]CP55940 as radioligand.
There is still a need for CB2 PET-tracers with improved
imaging profiles and high affinity and selectivity for CB2.
Such high affinity PET-radioligands may allow in vivo
visualization of the low density brain CB2 receptors. Moreover,
agonists preferentially bind to cannabinoid receptors in their
(functionally) activated conformation (Gullapalli et al., 2010).
Therefore, agonist CB2 PET-radioligands may allow visualization
of the activated fraction of the receptor which may correlate
better with CB2 related pathology of the receptor system. Here
we report the synthesis, radiosynthesis, and biological evaluation
of potent carbon-11 and a fluorine-18 labeled CB2 agonists
as potential PET tracers for in vivo imaging of brain CB2
receptors.
RESULTS
Synthesis and Radiolabelling
Compound 1 was synthesized using a previously reported
procedure where nitromethane (MeNO2) was treated with 10
M sodium hydroxide (NaOH) to form potentially explosive
methazoic acid 1. (Cheng et al., 2008; DiMauro et al., 2008)
Condensation of 1 with in situ generated ortho-aminoaldehyde
(3) formed 3-nitro-6-hydroxyquinoline 4, in 19% overall yield
starting from compound 2. Compound 4 was methylated using
methyl iodide (MeI) in the presence of potassium carbonate
(K2CO3) under reflux to give 3-nitro-6-methoxyquinoline 5a in
61% yield. Also compound 4 was converted into 5b in 67% yield,
using 1-Bromo-2-fluoroethane (FEtBr) and K2CO3 in DMF.
Finally, 6, 6a, and 6b were synthesized (36, 45, and 60% yields
respectively) by reducing the corresponding nitro compounds 4,
5a, and 5b respectively, via a standard reduction using iron (Fe)
powder/acetic acid (Figure 1).
The oxadiazole fragment (11) was synthesized as shown in
Figure 2. Commercially available 2-chloro-4-fluoro-benzonitrile
(7) was converted into an oxime (8) in 97% yield when
treated with hydroxylamine hydrochloride (NH2OH·HCl). The
oxadiazole core was formed by condensing 8 with succinic
anhydride and obtained in 28% yield after column purification.
The carboxylic acid (9) then underwent a Steglich esterification
(Neises and Steglich, 1978) with N,N′-dicyclohexylcarbodiimide
(DCC)/4-dimethylaminopyridine (DMAP) to form the desired
methyl ester (10) in 63% yield. The ester group of compound 10
was then subjected to diisobutylaluminium hydride (DIBAL-H)
reduction at −80◦C to form the corresponding aldehyde (11)
in 45% yield. Longer reaction times and increasing DIBAL-H
loading led to the formation of a side product, presumably the
corresponding alcohol.
The final reductive amination of 11 with 6a-c was performed
using an excess of titanium isopropoxide (Ti(O-iPr)4),
followed by reduction with sodium borohydride (NaBH4)
to form respectively, the desired precursor 3-(3-(3-(2-
chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)propylamino)
quinolin-6-ol (MA1, 57% yield) and reference compounds
N-(3-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)
propyl)-6-methoxyquinolin-3-amine (MA2, 49% yield), 6-
(2-Fluoroethoxy)-N-(3-(3-(2-chloro-4-fluorophenyl)-1,2,4-
oxadiazol-5-yl)propyl)quinolin-3-amine (MA3, 51% yield) as
shown in Figure 3. Compound 12 was synthesized using a
literature procedure and NMR and MS data matched reported
data (Cheng et al., 2008).
[11C]MA2 and [18F]MA3 were successfully produced via
a nucleophilic substitution reaction on the phenol moiety of
precursor MA1 using, respectively, [11C]MeI or 1-bromo-2-[18F]
fluoroethane ([18F]FEtBr) as presented in Figure 4. Carbon-11
methylation yields ranged from 34 to 47% of HPLC-recovered
radioactivity relative to [11C]MeI, with corresponding isolated
amounts of 1628–3145 MBq. Fluorine-18 alkylations yielded
isolated amounts of 617–706 MBq (24–68% of HPLC-recovered
radioactivity relative to [18F]FEtBr). The desired radiolabeled
compounds were separated from the precursor, unreacted
[11C]MeI or [18F]FEtBr, and side products by high-performance
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FIGURE 1 | Synthesis of substituted 3-amino quinolines (6a-c).
FIGURE 2 | Synthesis of the oxadiazole fragment 11.
liquid chromatography (HPLC) yielding over 98% pure
[11C]MA2 and over 99% pure [18F]MA3 with a specific activity
of 518 ± 284 GBq/µmol (n = 5) and 560 GBq/µmol (n = 2),
respectively. Non-radioactive MA2 or MA3 were co-injected
on the analytical HPLC system to confirm the identity of,
respectively, [11C]MA2 and [18F]MA3.
Biodistribution Studies
The tissue distribution and kinetics of [11C]MA2 and [18F]MA3
were studied in male NMRI mice at 2, 10, 30, and 60 min post
injection of the tracer. The results of the biodistribution studies
are presented in Table 1 ([11C]MA2) and Table 2 ([18F]MA3) as
percentage of injected dose (% ID) and standard uptake value
(SUV).
[11C]MA2 and [18F]MA3 were efficiently cleared from blood
(% ID 2 min/60 min ratio = 8.6 and 5.2, respectively) and all
major organs. Elimination of the tracers occurred predominantly
via the hepatobiliary pathway with excretion of radioactivity (via
liver) into the intestines ([11C]MA2: 63.8% ID and [18F]MA3:
64.4% ID at 60 min post injection) and to a lesser extent via renal
pathway, as urinary excretion was minimal with only 4.5% ID
([11C]MA2) and 1.6% ID ([18F]MA3) at 60 min after injection
of the tracers. This is expected, as usually compounds with
higher lipophilicity are expected to be excreted via hepatobiliary
pathway. The calculated logD and polar surface area (PSA) values
for [11C]MA2 [logD = 4.7; PSA = 73 Å (Mackie, 2008)] and
[18F]MA3 [clogD = 4.9; PSA = 73 Å (Mackie, 2008)]suggest
that the tracers may cross the blood-brain barrier (BBB) through
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FIGURE 3 | Final step to synthesize precursor MA1 and reference compounds MA2 and MA3 with structure of compound 12.
FIGURE 4 | Radiosynthesis of [11C]MA2 and [18F]MA3.
passive diffusion. In accordance, brain uptake of [11C]MA2
(1.6% ID at 2 min post injection) was higher than brain uptake
of [18F]MA3 (1.2% ID at 2 min post injection) although the
difference was not statistically significant (p = 0.7), but was
followed by a rapid wash-out from brain (% ID 2 min/60 min
ratio = 18.4 and 9.2, respectively). None of the studied organs,
except the liver (SUV = 2.0 and 2.1, respectively, at 60 min post
injection), retained [11C]MA2 or [18F]MA3.
Radiometabolites
The fraction of radiometabolites inmouse plasma at 2 and 30min
after injection of the tracer was determined by RP-HPLC analysis
to investigate the in vivo stability of [11C]MA2. The obtained data
show that [11C]MA2 is rapidly metabolized in vivo. At 2 min post
injection of [11C]MA2, 88% (n= 2) of the recovered radioactivity
was assigned to the intact parent tracer. The percentage of intact
[11C]MA2 decreased to 34% at 30min post injection of the tracer.
All detected radiometabolites were more polar than the intact
tracer.
Binding Profile
The results from the binding and functional assays are presented
in Table 3. MA2, MA3, and 12 behaved as agonists with an EC50
of, respectively, 3, 0.13, and 0.15 nM for human CB2 (hCB2)
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and an efficacy of 101, 102, and 100% in the cAMP assays.
Among the tested compoundsMA3 exhibited the highest binding
affinity (Ki) for hCB2 (Ki = 0.8 nM) and had about 4 times
higher affinity compared to 12, about 100 times higher affinity
compared to MA2 and 5 times higher affinity compared to
NE40. MA2 showed a lower selectivity toward the CB1 receptor
(Ki ratio hCB1/hCB2 = 19) compared with MA3 (Ki ratio
hCB1/hCB2 = 127), NE40 (Ki ratio hCB1/hCB2 = 241), and 12
(Ki ratio hCB1/hCB2= 202). NE40 behaved as an inverse agonist
in the cAMP assay displaying an EC50 of 8 nM for hCB2 and a
TABLE 1 | Tissue distribution of [11C]MA2 in control mice at 2 and 60 min
post injection (n = 4 per time point).
[11C]MA2 % IDa SUVb
2 min 60 min 2 min 60 min
Bladder + urine 0.2 ± 0.1 4.5 ± 1.0 – –
Kidneys 8.3 ± 1.6 1.0 ± 0.3 5.1 ± 0.7 0.6 ± 0.1
Liver 28.3 ± 2.9 9.1 ± 3.0 6.0 ± 0.1 2.0 ± 0.5
Spleen 0.5 ± 0.2 0.03 ± 0.01 2.0 ± 0.2 0.2 ± 0.0
Pancreas 1.6 ± 0.8 0.2 ± 0.1 2.2 ± 1.0 0.3 ± 0.0
Lungs 1.4 ± 0.3 0.1 ± 0.0 2.3 ± 0.4 0.2 ± 0.0
Heart 1.4 ± 0.4 0.1 ± 0.0 3.3 ± 0.6 0.1 ± 0.0
Intestines 9.7 ± 0.4 63.8 ± 2.9 – –
Stomach 1.3 ± 0.3 4.2 ± 3.9 – –
Brain 1.6 ± 0.5 0.1 ± 0.0 1.8 ± 0.2 0.1 ± 0.0
Blood 5.8 ± 0.4 0.7 ± 0.1 0.8 ± 0.1 0.1 ± 0.0
Mice were anesthetized with isoflurane (2% in oxygen) and injected i.v. with ∼9.25
MBq. Data are expressed as mean ± standard deviation; aPercentage of injected dose
calculated as counts per minute in organ/total counts per minute recovered; bStandard
uptake value calculated as (radioactivity as counts per minute in organ/weight of the organ
in grams)/(total counts recovered / body weight in grams).
negative efficacy (−178%). With NE40 no species difference in
binding affinity was observed.
DISCUSSION
The aim of this study was to synthesize new high-affinity
CB2 agonists, evaluate their brain uptake and potential for in
vivo visualization of peripheral and brain CB2 receptors. A
highly potent N-arylamide oxadiazole CB2 agonist was selected
from literature as lead compound for the development of our
radiolabeled analog 25. However, it should be noted that in the
paper of Cheng et al. (2008) the position of the nitrogen atom in
the biaryl moiety of the lead compound’s structure is incorrectly
indicated. A CB2 agonist PET-radioligand would allow to
study the functional state of the CB2 receptor system under
(patho)physiological conditions. The tracers were obtained in
favorable yields, with a high radiochemical purity and high
specific activity.
Though there may be some exceptions, the optimal logD
value for molecules to cross the BBB via passive diffusion is
assumed to be between 2.0 and 3.5 (Pike, 2009) and the PSA
value is ideally less than 90 Å (van de Waterbeemd et al.,
1998). As shown in Table 4, replacement of trifluoromethyl
group (12) with fluoroethyl group (MA3) leads to higher Ki and
EC50 values among the tested compounds both in mouse and
human varients whereas substitution of the trifluoromethyl with
a methyl group (MA2) decreases affinity. Despite slightly higher
lipophilicity for MA2 compared to MA3 (clogD = 4.7 and 4.9
respectively), [11C]MA2 have crossed the BBB efficiently (1.6
and 1.2% of ID at 2 min post injection respectively) and wash-
out from brain was rapid for both the tracers. The brain uptake
of [11C]MA2 was found to be similar to that of [11C]NE40 (%
ID = 1.7 in mouse brain at 2 min post injection) (Evens et al.,
2012) and in comparision to that of [11C]A-836339 (SUV ∼ 0.5
TABLE 2 | Tissue distribution of [18F]MA3 in control mice at 2, 10, 30, and 60 min post injection (n = 3 or 4 per time point).
[18F]MA3 % IDa SUVb
2 min 10 min 30 min 60 min 2 min 10 min 30 min 60 min
Bladder + urine 0.2 ± 0.2 0.4 ± 0.0 1.7 ± 0.3 1.6 ± 1.4 – – – –
Kidneys 9.0 ± 1.2 1.6 ± 0.2 1.0 ± 0.2 0.7 ± 0.3 5.4 ± 0.4 1.1 ± 0.1 0.6 ± 0.1 0.5 ± 0.1
Liver 31.4 ± 8.4 26.1 ± 3.4 17.3 ± 6.7 10.2 ± 5.2 7.2 ± 2.0 4.7 ± 0.7 3.7 ± 1.4 2.1 ± 1.1
Spleen 0.4 ± 0.1 0.3 ± 0.1 0.1 ± 0.0 0.03 ± 0.01 5.1 ± 0.6 0.5 ± 0.0 0.5 ± 0.3 0.5 ± 0.1
Pancreas 1.4 ± 0.3 0.4 ± 0.1 0.2 ± 0.1 0.1 ± 0.0 3.0 ± 0.5 0.8 ± 0.0 0.4 ± 0.1 0.3 ± 0.1
Lungs 1.2 ± 0.3 0.5 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 2.8 ± 0.7 0.7 ± 0.1 0.4 ± 0.1 0.3 ± 0.1
Heart 1.2 ± 0.1 0.3 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 3.4 ± 0.3 0.6 ± 0.0 0.4 ± 0.1 0.3 ± 0.0
Intestines 9.4 ± 3.9 30.8 ± 6.1 56.2 ± 5.4 64.4 ± 2.6 – – – –
Stomach 1.4 ± 0.2 0.5 ± 0.0 0.8 ± 1.0 4.4 ± 5.1 – – – –
Brain 1.2 ± 0.2 1.0 ± 0.1 0.3 ± 0.1 0.1 ± 0.0 1.1 ± 0.1 0.5 ± 0.0 0.2 ± 0.0 0.1 ± 0.0
Blood 5.4 ± 0.4 2.2 ± 0.3 1.2 ± 0.1 1.0 ± 0.3 0.8 ± 0.1 0.3 ± 0.0 0.2 ± 0.0 0.1 ± 0.0
Bone 5.3 ± 1.2 3.5 ± 0.2 1.6 ± 0.5 2.2 ± 0.3 0.4 ± 0.1 0.3 ± 0.0 0.1 ± 0.0 0.2 ± 0.0
Mice were anesthetized with isoflurane (2% in oxygen) and injected i.v. with ∼0.92 MBq. Data are expressed as mean ± standard deviation; aPercentage of injected dose calculated
as counts per minute in organ/total counts per minute recovered; bStandard uptake value calculated as (radioactivity as counts per minute in organ/weight of the organ in grams)/(total
counts recovered/body weight in grams).
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TABLE 3 | Radiometabolite analysis in blood plasma.
% of intact tracer in blood plasma (average of 2 assays) 2 min 30 min
[11C]MA2 88 34
TABLE 4 | Characterization of MA2, MA3, 12, and NE40 in functional cAMP
assays and radioligand binding assays with [3H]CP55940.
NE40 MA2 MA3 12
hCB2 cAMP EC50 [nM] (% eff) 8 (−178) 3 (101) 0.13 (102) 0.15 (100)
mCB2 cAMP EC50 [nM] (% eff) 11 (−128) 2 (100) 0.09 (101) 0.18 (100)
EC50 ratio hCB1/hCB2 > 1250 430 563 1300
hCB2 Ki [nM] 4 87 0.8 2.8
hCB1 Ki [nM] 1037 1611 102 568
Ki ratio hCB1/hCB2 241 19 127 202
mCB2 Ki [nM] 2 241 2.6 4.6
in rat brain at 2 min post injection) (Horti et al., 2010).
The biodistribution studies also showed that [11C]MA2 and
[18F]MA3 were cleared from blood via the hepatobiliary system,
as could be expected for compounds with lipophilic properties.
[11C]MA2 was substantially metabolized as a significant fraction
(> 60%) of unidentified polar radiometabolites was found in
plasma of mice at 30 min after injection of the tracer. Besides
the activity in the liver, due to metabolism and/or excretion of
the tracers, radioactivity in other major organs was negligible at
60 min after injection of [11C]MA2 or [18F]MA3. Retention of
the tracers in the spleen was anticipated, as this organ is known
to express high levels of CB2 (Lynn and Herkenham, 1994;
Galiegue et al., 1995). Surprisingly no accumulation of [11C]MA2
or [18F]MA3 was observed in the spleen and tracer washout from
the spleen was comparable to that from other organs such as the
pancreas and lungs. Previously, a lack of retention in the spleen
of mice and rats was also observed for other specific CB2 PET-
tracers including [11C]GW405833 (Evens et al., 2011), [18F]FE-
GW405833 (Evens et al., 2011), and a 18F-labeled 2-oxoquinoline
derivative (Turkman et al., 2012). The low spleen uptake could
also due to the lower binding affinity of [11C]GW405833 (35 nM)
and [18F]FE-GW405833 (27 nM) for CB2 or in the case of the
18F-labeled 2-oxoquinoline derivative a low specific activity (44.4
GBq/µmol) (Turkman et al., 2012). Also recently, a 1,3,5-triazine
based CB2 agonist labeled with fluorine-18 was reported to have
a low spleen uptake (0.39% ID/g, at 15min) (Yrjölä et al., 2015).
In general agonists bind to activated receptor sites, which only
represent a fraction of total binding sites, and this may explain
the low spleen uptake. However, the specific in vivo binding of
these tracers to CB2 receptors has to be established, experiments
with these two tracers on local overexpression of hCB2 in rats (as
previously shown) (Evens et al., 2011; Turkman et al., 2012) are
currently underway.
CONCLUSIONS
We successfully synthesized MA2 and MA3 and their in
vitro binding affinity for hCB2 was found to be 87 nM and
0.8 nM, respectively. Radiolabeled [11C]MA2 and [18F]MA3 was
obtained in relatively high yields, high radiochemical purity,
and high specific activity. Preliminary biodistribution studies
indicate favorable brain uptake and clearance from blood and
major organs. These preliminary results indicate [11C]MA2
and [18F]MA3 can be potential tracers for imaging brain CB2
receptors, in the view of their higher CB2 affinity and good
brain uptake. It has to be noted that, not many CB2 agonists are
available for pharmacologic studies that have both high affinity
and excellent brain uptake and the compounds described here
are suited to perform pharmacological experiments studying the
role of CB2 in CNS.
MATERIALS AND METHODS
General
2-Chloro-4-fluorobenzonitrile was purchased from TCI
Europe (Zwijndrecht, Belgium). All other chemicals and
solvents were obtained from Acros Organics (Geel, Belgium),
Sigma-Aldrich (Bornem, Belgium), or VWR International
(Leuven, Belgium). For ascending thin layer chromatography
(TLC), pre-coated aluminum backed plates (Silica gel 60
with fluorescent indicator UV 254 nm, 0.2mm thickness;
Macherey-Nagel, Düren, Germany) were used. Molecular
mass measurements were performed on a time-of-flight mass
spectrometer (LCT, Micromass, Manchester, UK) equipped
with an orthogonal electrospray ionization (ESI) interface.
Acquisition and processing of data was done using MassLynx
software (version 3.5, Micromass). Mass data were rounded
to the whole number. 1H nuclear magnetic resonance (NMR)
spectra were acquired with a Bruker Avance II spectrometer (400
MHz, 5mm probe, Fällanden, Switzerland). Chemical shifts are
reported in parts per million relative to tetramethylsilane (δ= 0).
Coupling constants are reported in hertz (Hz). Splitting patterns
are defined by s (singlet), d (doublet), t (triplet), or m (multiplet).
The clogD and PSA values were calculated using, respectively,
Marvinsketch 5.7.0 software and the calculator from Daylight
(http://www.daylight.com/meetings/emug00/Ertl/tpsa.html).
HPLC analysis was performed on an L2130 LaChrom Elite pump
(Hitachi, Tokyo, Japan) connected to a UV L2400 LaChrom
Elite spectrometer (Hitachi). Radiolabeled compounds were
analyzed by passage of the HPLC eluate (after passing through
the UV detector) over a 3-inch NaI(Tl) scintillation detector
connected to a single channel analyzer (GABI box; Raytest,
Straubenhardt, Germany). Data were acquired and analyzed
using a RaChel (Lablogic, Sheffield, UK) or GINA Star (Raytest)
data acquisition system. Quantification of radioactivity during
biodistribution and metabolite studies was performed using
an automated gamma counter equipped with a 3-inch NaI(Tl)
well crystal coupled to a multichannel analyzer, mounted in a
sample changer [2480 Wizard (Mackie, 2008), Perkin Elmer,
Massachusetts, USA]. The values are corrected for background
radiation, physical decay and counter dead time.
Animals were housed in individually ventilated cages in a
thermo-regulated (22◦C), humidity-controlled facility under a
12 h light/12 h dark cycle, with free access to food and water.
All animal experiments were performed in compliance with the
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principles set by the Belgian law relating to the conduct of animal
experimentation, after approval from the university (KU Leuven)
animal ethics committee.
Organic Synthesis
Methazoic Acid (1)
Caution:
Methazoic acid is a potential explosive, heat, and shock sensitive
compound. To a solution of 10MNaOH (3mL) at 0◦Cwas added
dropwise MeNO2 (0.5mL) and the resulting mixture was stirred
for 15 min. The reaction mixture was allowed to warm to room
temperature, stirred for 15 min and a second amount of MeNO2
(0.5mL) was added. After stirring until a clear brown solution
was formed (∼30 min), ice-cold water (50mL), and concentrated
hydrochloric acid (∼11.6 M HCl, 3mL) were slowly added to
the mixture. The resultant solution was extracted with diethyl
ether (Et2O; 2 × 100mL) and the organic layers were collected
and dried over magnesium sulfate (MgSO4). The solvent was
carefully removed under reduced pressure without heating to
yield compound 1 (∼1 g) as an orange-yellow viscous oil, which
was used in the synthesis of 4, without any further purification.
3-Nitro-6-Hydroxyquinoline (4)
Step A:
To a solution of 2-nitro-5-hydroxybenzaldehyde (2; 1.20 g,
7.18mmol, 1.0 eq) in ethanol (EtOH; 30mL) was added Fe
powder (1.48 g, 26.57mmol, 3.7 eq), followed by acetic acid
(2.4mL) and H2O (0.8mL). After stirring at room temperature
for 16 h, the dark brown reaction mixture was diluted with EtOH
(30mL), filtered through a sintered funnel, and concentrated in
vacuo. The crude mixture was extracted with dichloromethane
(DCM; 2× 200mL), the combined organic layers were dried over
MgSO4 and concentrated in vacuo. Compound 3 was obtained
as a crude yellow powder, which was used in step B without any
further purification.
Step B:
To a stirred solution of 3 in either tetrahydrofuran (THF) or
EtOH (10mL) was added a solution of compound 1 (∼1 g) in a
mixture of H2O (5mL) and 5 M HCl (5mL). The dark brown
mixture was heated to 80oC and stirred for 2 h. The solvent
was evaporated under reduced pressure, the crude material was
extracted with DCM (3 × 100mL) and the solution was again
concentrated under reduced pressure and purified over silica
column to give 4 as a pale brown solid. 1HNMR (CDCl3): δ 7.10–
7.17 (m, 1H, Ar), 7.41–7.45 (m, 1H, Ar), 8.11 (s, 1H, Ar), 8.67
(s, 1H, Ar), 9.24 (s, 1H, Ar). MS (ESI) m/z: 191.2 [(M+H)+,
100%].
3-Nitro-6-Methoxyquinoline (5a)
To a solution of compound 4 (260mg, 1.37mmol, 1 eq) in
acetone (15mL), K2CO3 (283mg, 2.05mmol, 1.5 eq) and MeI
(5 eq) were added and the reaction mixture was stirred at
60 ◦C for 4 h. Completion of reaction was confirmed by TLC
(EtOAc/heptane 1:1). Acetone was removed under reduced
pressure and the crude residue was diluted with DCM (100mL)
and washed with H2O (3 × 25mL). The organic layer was
dried over MgSO4 and the solvent was removed under reduced
pressure. Silica gel column purification yielded 5 (171mg) as pale
yellow crystalline needles. Yield: 61%. TLC (EtOAc/heptane 1:1):
Rf = 0.55. 1H NMR (CDCl3): δ 3.94 (s, 3H, OMe), 7.19–7.23 (m,
1H, Ar), 7.50–7.55 (m, 1H, Ar), 8.05 (s, 1H, Ar), 8.86 (s, 1H, Ar),
9.44 (s, 1H, Ar). MS (ESI) m/z: 205.2 [(M+H)+, 100%].
6-(2-Fluoroethoxy)-3-Nitroquinoline (5b)
To a solution of compound 4 (260mg, 1.37mmol, 1 eq) in DMF
(15mL), K2CO3 (283mg, 2.05mmol, 1.5 eq) and FEtBr (5 eq)
were added and the reaction mixture was stirred at 50◦C for 2 h.
Completion of reaction was confirmed by TLC (EtOAc/heptane
1:1). The crude residue was diluted with DCM (100mL) and
washed with H2O (3 × 25mL). The organic layer was dried
over MgSO4 and the solvent was removed under reduced
pressure. Silica gel column purification yielded 5b (230mg) as
pale yellow crystalline needles. Yield: 67%. TLC (EtOAc/heptane
1:1): Rf = 0.60. 1H NMR (CDCl3): δ 4.36 (dt, 2H, J 2.4 & 19.4),
4.84 (dt, 2H, J 2.4 & 39.2), 7.22 (s, 1H, Ar), 7.59 (d, 1H, J 9.2, Ar),
8.10 (d, 1H, J 9.2, Ar), 8.87 (s, 1H, Ar), 9.47 (s, 1H, Ar). MS (ESI)
m/z: 236.8 [(M+H)+, 100%].
3-Amino-6-Quinolinols (6a-c)
3-Aminoquinolin-6-ol (6a)To a solution of compound 4 (330mg,
1.74mmol, 1 eq) in EtOH (10mL), Fe powder (485mg,
8.68mmol, 5 eq) was added and the mixture was stirred. After
adding acetic acid (1mL) andH2O (0.2mL), the reactionmixture
was heated to 60oC and stirred for 3 h. The Fe powder was
removed by filtering the reaction mixture over a sintered funnel.
The filtrate was collected, dried over MgSO4 and concentrated
to yield 6a (100mg) as a pale yellow powder. Yield: 36%. TLC
(DCM/MeOH, 95:5): Rf = 0.21. MS (ESI) m/z: 161.0 [(M+H)+,
100%].
6-Methoxyquinolin-3-amine (6b) Compound 6b was
synthesized starting from compound 5a in accordance with
the procedure described for compound 6a. Yellow solid was
obtained in 45% yield. TLC (DCM/MeOH 95:5): Rf = 0.25. MS
(ESI) m/z: 174.7 [(M+H)+, 100%].
6-(2-Fluoroethoxy)quinolin-3-amine (6c) Compound 6c was
also synthesized starting from compound 5b as described
for compound 6a. Colorless powder was obtained in 60%
yield (175mg). RF 0.25 (9.5:0.5 DCM:MeOH). 1H NMR
(MeOD): δ 4.55 (dt, 2H, J 3.5 & 28.8), 5.01 (dt, 2H, J 3.4 & 47.8),
7.35 (d, 1H, J 9.2, Ar), 7.25 (s, 1H, Ar), 7.51 (s, 1H, Ar), 7.98 (d,
1H, J 9.2, Ar) 8.54 (s, 1H, Ar). MS (ESI) m/z: 206.9 [(M+H)+,
100%].
2-Chloro-4-Fluoro-N′-Hydroxybenzamidine (8)
To a solution of 2-chloro-4-fluoro-benzonitrile (7; 1.0 g,
6.45mmol, 1.0 eq) in MeOH was added NH2OH·HCl (0.58
g, 8.36mmol, 1.3 eq), Na2CO3 (1.0 g, 9.64mmol, 1.5 eq) and
H2O (4mL), and the reaction mixture was stirred for 4 h at
60◦C. The solvent was evaporated under reduced pressure and
the crude residue was extracted with DCM (2 × 500mL). The
combined organic layers were dried over MgSO4 and the solvent
was removed under reduced pressure. The crude compound 8
(1.18 g, 97%) was used as such in the next step without any further
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purification. RF 0.41 (1:1 hexane:EtOH). MS (ESI) m/z: 189.0
[(M+H)+, 100%].
3-(3-(2-Chloro-4-Fluorophenyl)-1,2,4-Oxadiazol-5-yl)
Propanoic Acid (9)
A solution of compound 8 (1.0 g, 5.32mmol, 1.0 eq) and succinic
anhydride (0.53 g, 5.32mmol, 1.0 eq) in toluene (15mL)
was stirred for 3 h at 110◦C. Toluene was evaporated under
reduced pressure, the crude residue was extracted with DCM
(3 × 250mL), the combined organic extracts were dried over
MgSO4 and concentrated under reduced pressure. The crude
residue was purified using silica gel column chromatography
(EtOAc/heptane gradient 10–30% EtOAc) and compound 9 was
obtained as a white solid (425mg). Yield: 28%. RF 0.25 (1:1
hexane:EtOH). 1H NMR (DMSO-d6): δ 2.56 (t, 2H, J 6.7, CH2),
2.94 (t, 2H, J 6.9, CH2), 7.11–7.18 (m, 1H, Ar), 7.39–7.44 (m,
1H, Ar), 7.65–7.71 (m, 1H, Ar). MS (ESI) m/z: 269.29 [(MH¬),
100%].
Methyl-3-(3-(2-Chloro-4-Fluorophenyl)-1,2,4-
Oxadiazol-5-yl)Propanoate (10)
Compound 9 (100mg, 0.370mmol, 1 eq) was dissolved
in dry DCM (4mL) followed by the addition of DCC
(229mg, 1.11mmol, 3 eq), DMAP (90mg, 0.740mmol, 2 eq),
and dry MeOH (0.5mL). The reaction mixture was stirred
for 16 h at room temperature. The reaction mixture was
concentrated under reduced pressure, DCM (50mL) was
added and the solution was washed with H2O (2 × 20mL).
After drying the organic layer over MgSO4, the solvent
was removed and the crude product purified through silica
gel column chromatography (EtOAc/heptane gradient 0–10%
EtOAc) yielded pure compound 10. Colorless oil (63% yield,
66mg). RF 0.55 (1:1 hexane:EtOH). 1H NMR (CDCl3): δ
2.54 (t, 2H, J 7.3, CH2), 2.89 (t, 2H, J 7.3, CH2), 3.33
(s, 3H, CH3), 6.66–6.72 (m, 1H, Ar), 6.85–6.89 (m, 1H,
Ar), 7.50–7.55 (m, 1H, Ar). MS (ESI) m/z: 285.1 [(MH+),
100%].
3-(3-(2-Chloro-4-Fluorophenyl)-1,2,4-Oxadiazol-5-
yl)Propanal (11)
To a solution of compound 10 (100mg, 0.352mmol, 1 eq)
in dry DCM (5mL) cooled to −80◦C was added drop-wise
over 5 min DIBAL-H 1.5 M in toluene (0.107mL, 0.528mmol,
1.5 eq) and the reaction mixture was stirred at the same
temperature for 1 h. The reaction was quenched with a few
drops of H2O, DCM (50mL) was added and the mixture
was washed with H2O (2 × 20mL). The organic layer was
dried over MgSO4 and the solvent was removed under reduced
pressure. The crude residue was purified through silica gel
flash chromatography using a mixture of heptane/EtOAc (2:1)
to yield the desired aldehyde 11 (40mg). Colorless powder
(40mg, 45%). RF 0.40 (1:1 hexane:EtOH). 1H NMR (CDCl3):
δ 2.72 (t, 2H, J 6.8, CH2), 2.87 (t, 2H, J 6.9, CH2),
6.67–6.70 (m, 1H, Ar), 6.85–6.89 (m, 1H, Ar), 7.54–7.56 (m,
1H, Ar), 9.49 (s. 1H, CHO). MS (ESI) m/z: 255.1 [(MH+),
100%].
N-(3-(3-(2-Chloro-4-Fluorophenyl)-1,2,4-Oxadiazol-5-
yl)Propyl)-6-Methoxyquinolin-3-Amine (MA2)
Compound 11 (87.0mg, 0.343mmol, 1 eq) and amine 6b
(60.0mg, 0.343mmol, 1 eq) were dissolved in dichloroethane
(DCE; 3mL), followed by the addition of Ti(O-iPr)4 (1.68mL,
5.142mmol, 15 eq) at room temperature. After stirring for 1 h,
the reaction mixture was added dropwise to a stirred solution
of NaBH4 (77.8mg, 2.057mmol, 6 eq) in dry MeOH (6mL) at
0oC. After the addition was complete the mixture was brought to
room temperature and stirred for 2 h. The reaction was quenched
with a few drops of 1M HCl and solvents were evaporated under
reduced pressure. The residue was dissolved in DCM (100mL),
the solution was washed with H2O (2 × 15mL) and the organic
layer was dried and concentrated by vacuum evaporation. The
crude product was purified over silica gel chromatography using
mixtures of DCM/MeOH as eluent. Pale yellow oil (70mg), yield:
49%. TLC (hexane/EtOH 1:1): Rf = 0.21. 1H NMR (CDCl3): δ
2.25–2.30 (m, 2H, H3b), 3.10–3.16 (m, 2H, H3c), 3.40 (t, 2H, J 6.7,
H3a), 3.87 (s, 3H, OMe), 6.86–6.88 (m, 1H, Ar), 6.94–6.97 (m, 1H,
Ar), 7.02–7.11 (m, 2H, Ar), 7.21–7.27 (m, 2H, Ar), 7.78–7.83 (m,
1H, Ar), 7.85–7.91 (m, 1H, Ar), 8.25 (br s, 1H, NH). MS (ESI)
m/z: 412 [(M+H)+, 100%].
3-(3-(3-(2-Chloro-4-Fluorophenyl)-1,2,4-Oxadiazol-5-
yl)Propylamino)Quinolin-6-ol (MA1)
MA1 was synthesized starting from compound 6a in accordance
with the procedure described forMA2. Pale yellow solid (90mg),
yield: 57%. TLC (hexane/EtOH 1:1): Rf = 0.20. MS (ESI) m/z:
398 [(M+H)+, 100%]. 1H NMR (CDCl3): δ 2.50–2.56 (m, 2H,
H3b), 3.40–3.46 (m, 2H, H3c), 3.60–3.65 (m, 2H, H3a), 7.16–7.26
(m, 4H, Ar), 7.42–7.48 (m, 1H, Ar), 7.65–7.70 (m, 1H, Ar), 8.09–
8.13 (m, 1H, Ar), 8.24–8.28 (m, 1H, Ar), 8.45 (s, 1H, NH). HRMS
(ESI) Calcd. for C20H17ClFN4O2 [M+H]+: 399.1018. Found:
399.1058.
6-(2-Fluoroethoxy)-N-(3-(3-(2-Chloro-4-Fluorophenyl)
-1,2,4-Oxadiazol-5-yl)Propyl)Quinolin-3-amine (MA3)
Yellow crystalline solid (55mg, 51%). RF 0.25 (1:1 hexane:EtOH).
1H NMR (CDCl3): δ 2.20–2.30 (m, 2H), 3.11 (t, 2H, J 7.2), 3.37
(t, 2H, J 6.8), 4.25 (dt, 2H, J 4.2 & 27.7), 4.77 (dt, 2H, J 4.1 &
47.4), 6.86 (d, 1H, J 2.7, Ar), 6.92 (d, 1H, J 2.6, Ar), 7.03–7.11 (m,
2H, Ar), 7.23–7.28 (m, 1H, Ar), 7.78–7.89 (m, 2H, Ar), 8.25 (d,
1H, J 2.7, Ar). HRMS (ESI) Calcd. for C22H20ClF2N4O2 (MH+):
445.1237. Found: 445.1276.
Radiosynthesis
[11C]CH3I and [18F]FEtBr were produced according to methods
described by Evens et al. (2008) and Chitneni et al. (2008),
respectively. [11C]CH3I was bubbled with a stream of helium
through a solution of the precursor MA1 (100 µg) and cesium
carbonate (Cs2CO3; 1–2mg) in dimethylformamide (DMF, 100
µL) until the radioactivity in the reaction vial was stabilized. The
reaction mixture was heated for 3min at 70◦C, diluted with 1mL
of water for injection and applied onto an HPLC column (Waters
XBridge RP-C18, 5 µm, 4.6 × 150mm) that was eluted with a
mixture of EtOH/sodium acetate (NaOAc) buffer 0.05M pH 5.5
(53:47 V/V) as mobile phase at a flow rate of 1mL/min. The
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desired product [11C]MA2 eluted after 11 min. [18F]FEtBr was
distilled with a stream of helium and passed through an ascarite
column (6 × 150mm) in a reaction vial containing MA1 (100
µg) and Cs2CO3 (1–2mg) in DMF (100 µL). After heating for 15
min at 90◦C, the reaction mixture was diluted with 1mL of water
for injection and injected on an XBridge column (5 µm, 4.6 ×
150mm) which was eluted with a mixture of EtOH/NaOAc 0.05
M pH 5.5 (45:55 V/V) at a flow rate of 1mL/min. The desired
product [18F]MA3 was collected after 20 min. Quality control
of [11C]MA2 and [18F]MA3 was performed on an analytical
HPLC system consisting of an XBridge column (RP-C18, 3.5µm,
3.0× 100mm; Waters) eluted with a mixture of CH3CN/NaOAc
buffer 0.05M pH 5.5 ([11C]MA2: 45:55 V/V and [18F]MA3: 40:60
V/V) at a flow rate of 0.8mL/min. UV detection was performed
at 254 nm.
Biodistribution Studies
The biodistribution of [11C]MA2 and [18F]MA3 was studied in
normal male Naval Medical Research Institute (NMRI) mice. A
solution of HPLC-purified [11C]MA2 or [18F]MA3 was diluted
with saline to obtain an ethanol concentration < 10%. Mice
were anesthetized with isoflurane (2% in oxygen) and injected
intravenously (i.v.) with [11C]MA2 (∼ 9.25 MBq) or [18F]MA3
(∼ 0.92 MBq) via a lateral tail vein. The mice were sacrificed
by decapitation at 2, and 60 min post injection (for [11C]MA2,
n = 4) and at 2, 10, 30, or 60 min post injection (for [18F]MA3,
n= 3 or 4 per time point) and dissected. Blood, organs, and other
body parts were collected in tared tubes and the radioactivity in
each tube was measured using an automated gamma counter.
The tubes containing selected organs and blood were weighed.
For calculation of total radioactivity in blood, blood mass was
assumed to be 7% of the body mass (Fritzberg et al., 1982).
Quantitative data are expressed as mean ± standard deviation
(SD). Means were compared using an unpaired two-tailed
student t-test. Values were considered statistically significant for
P ≤ 0.05.
Plasma Radiometabolite Analysis
After i.v. administration of [11C]MA2 (∼ 9.25 MBq) via a lateral
tail vein to anesthetized NMRI mice (isoflurane 2% in oxygen),
the mice were decapitated at 2 or 30 min post injection (n= 2 per
time point). Blood was collected into lithium heparin-containing
tubes (4.5-mL lithium heparin PST tubes, BD Vacutainer; BD,
Franklin Lakes, New Jersey) and stored on ice. The blood samples
were centrifuged for 10 min at 3000 rpm to separate the plasma.
The isolated plasma was spiked with authentic non-radioactive
MA2 (15 µL of 1mg/mL solution in CH3CN) and analyzed by
RP-HPLC on a Chromolith RP C18 column (3mm x 100mm;
Merck) eluted with gradient mixtures of CH3CN (A) and 0.05
M NaOAc pH 5.5 (B) (0–5 min: Isocratic 100% B, flow rate
of 0.5mL/min; 5–10 min: Linear gradient 100 B to 10% B,
flow rate of 1mL/min; 10–13 min: Isocratic 10% B, flow rate
of 1mL/min; 13–13.1 min: Linear gradient 10 B to 100% B,
flow rate of 0.5mL/min; 13.1–15 min: Isocratic 100% B, flow
rate of 0.5mL/min). After passing through a UV detector (254
nm) and an in-line 3-inch NaI(Tl) scintillation detector, the
HPLC eluate was collected as 0.5- or 1-mL fractions (model 2110
fraction collector, Biorad, Hercules, CA). The radioactivity in all
fractions was measured using an automated gamma counter. The
recovery of the injected radioactivity from the HPLC apparatus
and Chromolith column was 94.9± 0.9 % (n= 4).
Functional and Binding Experiments
The competition binding experiments and functional assays were
performed by Roche Healthcare.
Cell Culture
CHO-K1 beta-arrestin cells (DiscoveRx, Fremont, CA)
expressing hCB2, mouse CB2 (mCB2), and human CB1 (hCB1)
were cultured in F-12 Nutrient Mixture (HAM) supplemented
with 10% fetal bovine serum (FBS), 300 µg/mL hygromycin
and 800 µg/mL geneticin (G418). Cells were incubated in a
humidified atmosphere at 37◦C with 5% CO2.
cAMP Assay
cAMP was measured using cAMP-Nano-TRF detection kit
(Roche Diagnostics, Penzberg, Germany). Cells were seeded
17–24 h prior to the experiment 3 × 104 cells per well
in a black 96-well plate with flat clear bottom (Corning,
Wiesbaden, Germany) in growth medium and incubated in
5% CO2 at 37◦C in a humidified incubator. The growth
medium was exchanged with Krebs Ringer bicarbonate buffer
with 1mmol/L 3-isobutyl-1-methylxanthine (IBMX), 0.1% fatty
acid-free bovine serum albumin (BSA) and incubated at 30◦C
for 60 min. Agonist was added to a final assay volume
of 100 µL and the mixture was incubated for 30 min at
30◦C. The assay was stopped by the addition of 50 µL 3x
lysis reagent and shaken for 2 h at room temperature. The
time-resolved energy transfer was measured using an LF502
Nanoscan FLT (IOM, Berlin, Germany), equipped with a laser
as excitation source. cAMP content was determined from the
function of a standard curve spanning from 10 to 0.13 nmol/L
cAMP.
Radioligand Binding Assay
Stably transfected cells were treated for 24 h with 5mM
butyrate in growth medium before harvesting, followed by
homogenization in 15 mmol/L Hepes, 0.3mmol/L EDTA,
1mmol/L EGTA, 2mmol/L MgCl2, complete EDTA-free
protease inhibitor (Roche Applied Science, Rotkreuz,
Switzerland), pH 7.4 using a glass potter and centrifugation
at 47,800 g at 4◦C for 30min. The pellet was then rehomogenized
twice in the same buffer and centrifuged (47,800 g, 4◦C, 30
min). The final pellet was then resuspended in 75mmol/L
Tris, 0.3mmol/L EDTA, 1mmol/L EGTA, 12.5mmol/L MgCl2,
250mmol/L sucrose, pH 7.4 at a protein concentration of
1 to 3mg/mL, aliquoted, frozen on dry ice and stored at
−80◦C. Saturation binding was performed with 0.05 to 2.6
nM [3H]CP55940 (Perkin Elmer) and 1.0 µg of membrane
protein. CP55940 (10 µM) was used to define non-specific
binding. More than 95% of the total binding signal was specific.
Assay buffer consisted of 50mmol/L Tris-HCl, 5mmol/L
MgCl2, 2.5mmol/L EGTA, and 0.1% fatty acid-free BSA, pH
7.4. Assays were initiated by addition of membranes in a final
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volume of 250 µL/well. Mixtures were incubated for 3 h at
room temperature and then vacuum filtered and rinsed with
wash buffer (50mmol/L Tris-HCl, 5mmol/L MgCl2, 2.5mmol/L
EGTA, and 0.5% fatty acid-free BSA, pH 7.4) on a Filtermate
cell harvester through Packard GF/B filters presoaked in 0.3%
polyethylenimine.
For competition binding, membrane preparations were
incubated with 0.3 nM [3H]CP55940 in the presence or absence
of increasing concentrations of ligands for 60 min at 30◦C in
a final volume of 0.2mL of 50mmol/L Tris-HCl, 5mmol/L
MgCl2, 2.5mmol/L EGTA, 0.1% fatty acid-free BSA, and 1%
DMSO, pH 7.4, buffer, gently shaking. Non-specific binding
was defined with 10 µM CP55940. All binding reactions were
terminated by vacuum filtration onto 0.5% polyethylenimine
presoaked GF/B filter plates (Packard) followed by seven brief
washes with 2mL of ice-cold binding buffer containing 0.5%
fatty acid-free BSA. Plates were dried at 50◦C for 1 h and
liquid scintillation counting was used to determine bound
radiolabel. IC50 values and Hill slopes were determined by a
four parameter logistic model using ActivityBase (ID Business
Solution, Guilford, UK). pKi values were determined by the
generalized Cheng-Prusoff equation (Yung-Chi and Prusoff,
1973).
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